Morphic Therapeutic nets $80 mln Series B
Morphic Therapeutic, a developer of oral integrin therapies, has raised $80 million in Series B financing. Omega Funds and Novo Holdings led the round with participation from other investors that included Invus and EcoR1 Capital.
26 September 2018•1 min read
